Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome

Although hypomethylating therapy (HMT) is the first line therapy in higher-risk myelodysplastic syndromes (MDS), predicting response to HMT remains an unresolved issue. We aimed to identify mutations associated with response to HMT and survival in MDS. A total of 107 Korean patients with MDS who und...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Seung-Hyun, Kim, Yoo-Jin, Yim, Seon-Hee, Kim, Hye-Jung, Kwon, Yong-Rim, Hur, Eun-Hye, Goo, Bon-Kwan, Choi, Yun-Suk, Lee, Sug Hyung, Chung, Yeun-Jun, Lee, Je-Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342416/
https://www.ncbi.nlm.nih.gov/pubmed/27419369
http://dx.doi.org/10.18632/oncotarget.10526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342416/
https://www.ncbi.nlm.nih.gov/pubmed/27419369
http://dx.doi.org/10.18632/oncotarget.10526

Ejemplares similares